0.6746
Lexaria Bioscience Corp stock is traded at $0.6746, with a volume of 345.45K.
It is down -4.23% in the last 24 hours and down -35.88% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.7097
Open:
$0.7146
24h Volume:
345.45K
Relative Volume:
0.55
Market Cap:
$16.82M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.5332
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+24.99%
1M Performance:
-35.88%
6M Performance:
-24.48%
1Y Performance:
-68.82%
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LEXX
Lexaria Bioscience Corp
|
0.6758 | 17.66M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network
Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan
Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда
What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда
Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда
Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда
Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда
Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда
How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber
Published on: 2025-12-19 15:15:39 - DonanımHaber
Published on: 2025-12-19 14:32:21 - DonanımHaber
Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда
Lexaria Bioscience Corp (LEXX) is a good investment, but the stock may be undervalued - uspostnews.com
Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -
Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com
Lexaria Bioscience closes $3.5 million registered direct offering By Investing.com - Investing.com Canada
Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bluefield Daily Telegraph
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):